Atyr Pharma Inc ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company develops ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders; and develops and tests ATYR2810, the Company's monoclonal antibody that targets the neuropilin-2 (NRP2) receptor for the treatment of aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company has a research collaboration with Albert Einstein College of Medicine to further the development and testing of ATYR2810. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.